WO2004074320A3 - Nouvelles cibles therapeutiques pour le cancer - Google Patents

Nouvelles cibles therapeutiques pour le cancer Download PDF

Info

Publication number
WO2004074320A3
WO2004074320A3 PCT/US2004/004730 US2004004730W WO2004074320A3 WO 2004074320 A3 WO2004074320 A3 WO 2004074320A3 US 2004004730 W US2004004730 W US 2004004730W WO 2004074320 A3 WO2004074320 A3 WO 2004074320A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
present
provides
therapeutic targets
detection
Prior art date
Application number
PCT/US2004/004730
Other languages
English (en)
Other versions
WO2004074320A2 (fr
WO2004074320A8 (fr
Inventor
David W Morris
Marc S Malandro
Original Assignee
Sagres Discovery Inc
David W Morris
Marc S Malandro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/367,094 external-priority patent/US20040170982A1/en
Priority claimed from US10/388,838 external-priority patent/US20040180344A1/en
Priority claimed from US10/417,375 external-priority patent/US20040219528A1/en
Priority claimed from US10/461,862 external-priority patent/US7767387B2/en
Priority claimed from US10/663,431 external-priority patent/US20070218071A1/en
Priority claimed from US10/737,318 external-priority patent/US20050202442A1/en
Priority to EP04711933A priority Critical patent/EP1594893A2/fr
Priority to US10/545,777 priority patent/US20060228710A1/en
Priority to CA002516128A priority patent/CA2516128A1/fr
Application filed by Sagres Discovery Inc, David W Morris, Marc S Malandro filed Critical Sagres Discovery Inc
Priority to JP2006503661A priority patent/JP2009520459A/ja
Priority to AU2004213432A priority patent/AU2004213432A1/en
Publication of WO2004074320A2 publication Critical patent/WO2004074320A2/fr
Publication of WO2004074320A8 publication Critical patent/WO2004074320A8/fr
Publication of WO2004074320A3 publication Critical patent/WO2004074320A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouvelles séquences à utiliser pour la détection, pour le diagnostic et pour le traitement de cancers, en particulier de lymphomes. L'invention concerne des séquences polynucléotidiques associées au cancer (CA), dont l'expression est associée au cancer. L'invention concerne des polypeptides CA associés au cancer, situés sur la surface cellulaire, et de nouvelles cibles thérapeutiques contre le cancer. L'invention concerne également des compositions et des méthodes de diagnostic pour la détection du cancer. L'invention concerne des anticorps monoclonaux et polyclonaux spécifiques aux polypeptides CA. L'invention concerne également des outils de diagnostic, des compositions et des méthodes thérapeutiques pour le criblage, la prévention et le traitement du cancer.
PCT/US2004/004730 2003-02-14 2004-02-17 Nouvelles cibles therapeutiques pour le cancer WO2004074320A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004213432A AU2004213432A1 (en) 2003-02-14 2004-02-17 Novel therapeutic targets in cancer
JP2006503661A JP2009520459A (ja) 2003-02-14 2004-02-17 癌における治療標的
EP04711933A EP1594893A2 (fr) 2003-02-14 2004-02-17 Cibles therapeutiques pour le cancer
CA002516128A CA2516128A1 (fr) 2003-02-14 2004-02-17 Nouvelles cibles therapeutiques pour le cancer
US10/545,777 US20060228710A1 (en) 2003-02-14 2004-02-17 Novel therapeutic targets in cancer

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US10/367,094 US20040170982A1 (en) 2003-02-14 2003-02-14 Novel therapeutic targets in cancer
US10/367,094 2003-02-14
US10/388,838 2003-03-14
US10/388,838 US20040180344A1 (en) 2003-03-14 2003-03-14 Novel therapeutic targets in cancer
US10/417,375 US20040219528A1 (en) 2003-04-15 2003-04-15 Novel therapeutic targets in cancer
US10/417,375 2003-04-15
US10/461,862 2003-06-13
US10/461,862 US7767387B2 (en) 2003-06-13 2003-06-13 Therapeutic targets in cancer
US10/663,431 US20070218071A1 (en) 2003-09-15 2003-09-15 Novel therapeutic targets in cancer
US10/663,431 2003-09-15
US10/737,318 US20050202442A1 (en) 2003-12-15 2003-12-15 Novel therapeutic targets in cancer
US10/737,318 2003-12-15

Publications (3)

Publication Number Publication Date
WO2004074320A2 WO2004074320A2 (fr) 2004-09-02
WO2004074320A8 WO2004074320A8 (fr) 2004-12-09
WO2004074320A3 true WO2004074320A3 (fr) 2005-06-02

Family

ID=32913375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004730 WO2004074320A2 (fr) 2003-02-14 2004-02-17 Nouvelles cibles therapeutiques pour le cancer

Country Status (6)

Country Link
US (1) US20060228710A1 (fr)
EP (2) EP2196474A3 (fr)
JP (2) JP2009520459A (fr)
AU (1) AU2004213432A1 (fr)
CA (1) CA2516128A1 (fr)
WO (1) WO2004074320A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044209A2 (fr) 2000-11-28 2002-06-06 Zymogenetics, Inc. Zcytor19, recepteur de la cytokine
EP1497415B1 (fr) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methodes d'identification ou modulation de l'interaction d'un recepteur de cytokine et son ligand
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
ES2687786T3 (es) 2004-04-21 2018-10-29 Alexion Pharmaceuticals, Inc. Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (fr) 2004-09-23 2013-12-10 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
WO2006055927A2 (fr) * 2004-11-17 2006-05-26 The Cleveland Clinic Foundation Gene et proteine pathogenes associes a la dyskinesie paroxystique et a l'epilepsie
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
CA2612225A1 (fr) * 2005-06-21 2007-01-04 Cyto Pulse Sciences, Inc. Procedes et compositions relatifs a un vaccin contre le cancer de la prostate
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
WO2007084790A2 (fr) 2006-01-20 2007-07-26 Glenbrook Associates, Inc. Système et procédé pour base de données optimisée à contexte riche pour traitement de concepts
DK2069793T3 (en) 2006-08-29 2017-04-24 Oxford Biotherapeutics Ltd IDENTIFICATION OF PROTEIN IN CONNECTION WITH HEPATOCELLULAR CARCINOMA, GLIOBLASTOMA AND LUNG CANCER
WO2008069621A1 (fr) * 2006-12-08 2008-06-12 Korea Research Institute Of Bioscience And Biotechnology Nouvelle utilisation de gènes mig12 et pio5
US8362224B2 (en) * 2006-12-19 2013-01-29 The Trustees Of The University Of Pennsylvania Screening for CD93 (C1qRp)-associated polymorphism(S) in the diagnosis, prevention and treatment of autoimmune diseases
WO2008128144A2 (fr) * 2007-04-15 2008-10-23 Shuang Zhang Système de sélection d'anticorps monoclonal, et fabrication et utilisation de celui-ci
ES2376509T3 (es) 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
GB0714842D0 (en) * 2007-07-31 2007-09-12 Imp Innovations Ltd Methods
WO2009020521A2 (fr) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification et traitement de tumeurs de la prostate répondant aux œstrogènes
DE102008045696A1 (de) * 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
US8993343B2 (en) * 2009-01-28 2015-03-31 Korea Research Institute Of Bioscience And Biotechnology CD93 or use of soluble fragment thereof
EA028336B1 (ru) 2009-03-05 2017-11-30 МЕДАРЕКС Л.Л.Си. Полностью человеческие антитела, специфические в отношении cadm1
EP2448966B1 (fr) 2009-07-03 2018-11-14 Avipep Pty Ltd Immunoconjugués et leurs procédés de production
IN2012DN03025A (fr) 2009-09-09 2015-07-31 Ct Se Llc
US9938582B2 (en) 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2011075786A1 (fr) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugués et leurs méthodes de production
EA024701B1 (ru) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
CA2799540A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP2658979B1 (fr) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation
WO2012114339A1 (fr) 2011-02-23 2012-08-30 Rappaport Family Institute For Research In The Medical Sciences Molécules de haute affinité capables de se lier à un récepteur plexine de type a et leurs utilisations
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
CA2833212C (fr) 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
JP6487839B2 (ja) 2012-03-15 2019-03-20 ヤンセン バイオテツク，インコーポレーテツド ヒト抗ｃｄ２７抗体、方法、及び使用
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pirrolobenzodiazepine anti-CD22 antibody conjugates
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
AU2014307080B2 (en) 2013-08-12 2018-06-07 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
CA2928952A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes peptidomimetiques et conjugues anticorps-medicament de ceux-ci
JP6895254B2 (ja) 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
CA2929565A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes conjugues anticorps-medicament dimerique a base de 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
MA40575A (fr) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (fr) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp)
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
EP3368062A4 (fr) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017155569A1 (fr) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez l'enfant
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
EP3436020A4 (fr) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
WO2017214130A1 (fr) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Impact du métal sur la production des phosphatases alcalines
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
DK3476865T3 (da) * 2016-06-28 2023-12-18 Biocytogen Pharmaceuticals Beijing Co Ltd Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
EP3496763A1 (fr) 2016-08-11 2019-06-19 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
EP3522933B1 (fr) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3045386A1 (fr) * 2016-12-09 2018-06-14 Onkimmune Limited Cellules tueuses naturelles modifiees et leurs utilisations
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
MX2019011508A (es) 2017-03-31 2019-11-01 Alexion Pharma Inc Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes.
WO2018192944A1 (fr) 2017-04-18 2018-10-25 Medimmune Limited Conjugués de pyrrolobenzodiazépine
EP3612234B1 (fr) 2017-04-20 2024-03-13 ADC Therapeutics SA Polythérapie avec un conjugué anticorps anti-axl-médicament
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
WO2019072241A1 (fr) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec pd-1 humain ou chimérique
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114507695B (zh) * 2022-02-17 2023-09-19 四川大学华西医院 一种用于调控神经元活性的重组载体和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057497A2 (fr) * 2001-01-18 2002-07-25 The Regents Of The University Of California Clonage de protooncogenes a rendement eleve
US20020132237A1 (en) * 2000-05-26 2002-09-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055133A1 (fr) * 1997-06-06 1998-12-10 The Regents Of The University Of California Antigene associe a un melanome, epitopes des cellules t et leurs procedes d'utilisation
US6345375B1 (en) * 1999-02-24 2002-02-05 California Amplifier, Inc. Packet-based communication methods and systems having improved data throughput
WO2003004989A2 (fr) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, trousses, et procedes d'identification, d'evaluation, de prevention, et de therapie pour le cancer du sein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132237A1 (en) * 2000-05-26 2002-09-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002057497A2 (fr) * 2001-01-18 2002-07-25 The Regents Of The University Of California Clonage de protooncogenes a rendement eleve
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARIHIRO K ET AL: "Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma.", BREAST CANCER (TOKYO, JAPAN) JAN 2000, vol. 7, no. 1, January 2000 (2000-01-01), pages 19 - 26, XP008038846, ISSN: 1340-6868 *
AUGENLICHT L H ET AL: "CLONING AND SCREENING OF SEQUENCES EXPRESSED IN A MOUSE COLON TUMOR", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 42, no. 3, March 1982 (1982-03-01), pages 1088 - 1093, XP000929512, ISSN: 0008-5472 *
BERNS A: "PROVIRUS TAGGING AS AN INSTRUMENT TO IDENTIFY ONCOGENES AND TO ESTABLISH SYNERGISM BETWEEN ONCOGENES", ARCHIVES OF VIROLOGY, NEW YORK, NY, US, vol. 102, no. 1/2, 1988, pages 1 - 18, XP008012759, ISSN: 0304-8608 *
HIBI KENJI ET AL: "Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer", ONCOGENE, vol. 9, no. 2, 1994, pages 611 - 619, XP008038818, ISSN: 0950-9232 *
JONKERS JOS ET AL: "Retroviral insertional mutagenesis as a strategy to identify cancer genes", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1287, no. 1, 1996, pages 29 - 57, XP008038878, ISSN: 0006-3002 *
KHAN J ET AL: "EXPRESSION PROFILING IN CANCER USING CDNA MICROARRAYS", ELECTROPHORESIS, WEINHEIM, DE, vol. 20, no. 2, February 1999 (1999-02-01), pages 223 - 229, XP008002229, ISSN: 0173-0835 *
LI J ET AL: "Leukaemia disease genes: Large-scale cloning and pathway predictions", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 23, no. 3, November 1999 (1999-11-01), pages 348 - 353, XP002223354, ISSN: 1061-4036 *
MIKKERS H ET AL: "HIGH-THROUGHPUT RETROVIRAL TAGGING TO IDENTIFY COMPONENTS OF SPECIFIC SIGNALING PATHWAYS IN CANCER", NATURE GENETICS, NEW YORK, NY, US, vol. 32, September 2002 (2002-09-01), pages 153 - 159,I,331, XP001148101, ISSN: 1061-4036 *
PALMER ELISE L ET AL: "Sequence and tissue distribution of the integrin alpha-9 subunit, a novel partner of beta-1 that is widely distributed in epithelia and muscle", JOURNAL OF CELL BIOLOGY, vol. 123, no. 5, 1993, pages 1289 - 1297, XP002305856, ISSN: 0021-9525 *
ZHANG L ET AL: "Gene expression profiles in normal and cancer cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 276, 23 May 1997 (1997-05-23), pages 1268 - 1272, XP002083785, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
EP1594893A2 (fr) 2005-11-16
JP2010263894A (ja) 2010-11-25
EP2196474A2 (fr) 2010-06-16
JP2009520459A (ja) 2009-05-28
WO2004074320A2 (fr) 2004-09-02
EP2196474A3 (fr) 2010-12-15
US20060228710A1 (en) 2006-10-12
AU2004213432A1 (en) 2004-09-02
WO2004074320A8 (fr) 2004-12-09
CA2516128A1 (fr) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2004074320A3 (fr) Nouvelles cibles therapeutiques pour le cancer
WO2005031001A3 (fr) Nouvelles cibles therapeutiques pour le traitement du cancer
WO2005104810A3 (fr) Nouveaux cibles therapeutiques dans le cancer
WO2004058146A3 (fr) Nouvelles compositions et nouveaux procedes de traitement du cancer
WO2004060304A3 (fr) Compositions et procedes pour la cancerotherapie
WO2005107396A3 (fr) Compositions et procedes nouveaux dans le domaine du cancer
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2005080431A3 (fr) Anticorps monoclonaux bloquant specifiquement l'activite biologique d'un antigene tumoral
WO2004100870A3 (fr) Compositions et procedes d'immunotherapie specifique a wt1
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2004060302A3 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
WO2006038955A3 (fr) Nouvelles cibles therapeutiques contre le cancer
WO2003080808A3 (fr) Nouvelles compositions et nouveaux procedes pour le cancer
WO2005085861A3 (fr) Acides nucleiques et polypeptides codes destines a etre utilises dans des troubles hepatiques et du cancer epithelial
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
WO2007107774A3 (fr) Nouvelles méthodes de diagnostic et de traitement
WO2005058251A3 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
WO2004060301A3 (fr) Nouvelles compositions et procedes utilises dans le cadre du cancer
WO2004029287A3 (fr) Polypeptides et acides nucleiques codant ceux-ci et utilisation de ceux-ci pour la prevention, le diagnostic ou le traitement de troubles du foie et du cancer epithelial
WO2004101762A3 (fr) Detection et traitement des cancers du colon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 36/2004 UNDER (72, 75) REPLACE "MORRIS, DAVID, W. [US/US]; 2841 EMERALD BAY DRIVE, DAVIS, CA 95616 (US).MORRIS, DAVID, W. [US/US]; 2841 EMERALD BAY DRIVE, DAVIS, CA 95616 (US)." BY "MORRIS, DAVID, W. [US/US]; 2841 EMERALD BAY DRIVE, DAVIS, CA 95616 (US)."

WWE Wipo information: entry into national phase

Ref document number: 2516128

Country of ref document: CA

Ref document number: 2004213432

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006503661

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004213432

Country of ref document: AU

Date of ref document: 20040217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004213432

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004711933

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004711933

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006228710

Country of ref document: US

Ref document number: 10545777

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10545777

Country of ref document: US